New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
In Philadelphia on June 08, 2026, Century Therapeutics, Inc. (NASDAQ: IPSC), a biotech firm specializing in induced pluripotent stem cell (iPSC)-derived treatments for autoimmune illnesses like type 1 diabetes (T1D) and cancer, revealed fresh preclinical data on CNTY-813. This iPSC-derived islet replacement therapy, enhanced with Allo-Evasion™ 5.0, was showcased in an oral presentation at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, Louisiana.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments